Cannabichromene
A non-psychoactive cannabinoid with potent anti-inflammatory and antidepressant properties
Cannabichromene (CBC) is the third most abundant cannabinoid in cannabis and one of the least studied major cannabinoids. It is non-psychoactive and has demonstrated significant anti-inflammatory, antidepressant, and neurogenic properties in preclinical research. CBC is particularly notable for its role in promoting neurogenesis — the growth of new brain cells.
Primary Receptors & Targets
CBC's pharmacology is distinct from other cannabinoids in that it has minimal affinity for CB1 and CB2 receptors. Instead, CBC primarily acts through transient receptor potential (TRP) channels — particularly TRPV1, TRPA1, and TRPV4 — which are involved in pain, inflammation, and temperature sensation.
CBC's antidepressant effects appear to involve raising endocannabinoid tone: CBC inhibits the reuptake of anandamide and 2-AG, similar to CBD's FAAH inhibition mechanism. Elevated anandamide levels in the limbic system may contribute to mood elevation.
CBC's neurogenic effects — its ability to promote the growth and survival of neural progenitor cells — are particularly intriguing. Neurogenesis in the adult hippocampus is associated with antidepressant effects and cognitive resilience. CBC's promotion of neural stem cell viability in vitro suggests a mechanism that could be relevant to both depression and neurodegenerative disease.
2010 study found CBC produced antidepressant effects in the forced swim test, contributing to the overall antidepressant profile of cannabis.
CBC promoted neural stem cell viability and differentiation in vitro — a mechanism relevant to neurological disease and cognitive health.
CBC inhibited edema in animal models; TRPV1/TRPA1 activation modulates pain signaling in sensory neurons.
2016 study found CBC reduced sebaceous gland lipid production and inflammation — two key drivers of acne pathology.
CBC demonstrated activity against E. coli, S. aureus, and several fungal species in vitro.
Evidence levels reflect the current state of clinical and preclinical research. Preliminary evidence does not constitute medical advice. Consult a healthcare provider before using cannabinoids therapeutically.
Neurochemistry International
CBC increased the viability of neural stem progenitor cells and promoted their differentiation into astrocytes, suggesting a role in adult neurogenesis.
Psychopharmacology
CBC produced significant antidepressant effects in the forced swim test, and the combination of CBC with THC produced greater antidepressant effects than either alone.
Experimental Dermatology
CBC normalized lipid production in sebocytes and reduced inflammation, suggesting therapeutic potential for acne vulgaris.
One of the most intriguing findings in CBC research is its ability to promote neurogenesis — the growth of new neurons — in the adult brain. A 2013 study found that CBC increased the viability of neural stem progenitor cells and promoted their differentiation into astrocytes. This is significant because adult hippocampal neurogenesis is strongly associated with antidepressant effects and cognitive resilience. The leading neurogenesis theory of depression holds that antidepressants work partly by promoting new neuron growth in the hippocampus — and CBC appears to share this mechanism. This makes CBC a potentially important component of full-spectrum cannabis products for mood and cognitive health.